Literature DB >> 12019077

Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance.

Letizia Angiolella1, Mia M Micocci, Simona D'Alessio, Antonietta Girolamo, Bruno Maras, Antonio Cassone.   

Abstract

Identification of major glucan-associated proteins (GAPs) of the cell wall of a number of Candida albicans isolates susceptible or resistant to fluconazole (FLC) was addressed by direct sequencing of the protein bands resolved by unidimensional gel electrophoresis. Changes in the GAP compositions of the different strains grown in the presence of the drug were also investigated. In the FLC-susceptible strains, the major (more abundant) GAPs were enolase (46 kDa), two isoforms of phosphoglyceromutase (32 and 29 kDa), and two beta-(1-3)-exoglucanases (44 and 34 kDa), one of which (the 34-kDa component) was glycosylated. When these strains were grown in the presence of FLC there were substantial decreases in the intensities of the two enzymes of the glycolytic pathway (enolase and the phosphoglyceromutases), which were apparently replaced by enhancement of the exoglucanase constituents, particularly the 44-kDa one. This GAP pattern closely mimicked that observed in the FLC-resistant strains whether they were grown in the presence or in the absence of the drug. Both the enolase and the exoglucanase constituents were detected in the culture supernatants of FLC-treated cells, together with substantial amounts of highly glycosylated, probably mannoprotein secretory material, suggesting that FLC may cause marked alterations of GAP incorporation into the cell wall. Altogether, we were able to identify all major GAP constituents and monitor their distributions in the cell wall of C. albicans during treatment with FLC. The near equivalence of the GAP profile for the FLC-susceptible strain grown in the presence of FLC to that for the FLC-resistant strain suggests that the effects of the drug on GAPs may be stably incorporated into the cell wall of the fungus upon acquisition of resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019077      PMCID: PMC127269          DOI: 10.1128/AAC.46.6.1688-1694.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans.

Authors:  K C Hazen; G Mandell; E Coleman; G Wu
Journal:  FEMS Microbiol Lett       Date:  2000-02-01       Impact factor: 2.742

2.  Dimorphism in Candida albicans: contribution of mannoproteins to the architecture of yeast and mycelial cell walls.

Authors:  M V Elorza; A Murgui; R Sentandreu
Journal:  J Gen Microbiol       Date:  1985-09

3.  Exo-1,3-beta-glucanase activity in Candida albicans: effect of the yeast-to-mycelium transition.

Authors:  M Molina; R Cenamor; C Nombela
Journal:  J Gen Microbiol       Date:  1987-03

4.  Enolase is present in the cell wall of Saccharomyces cerevisiae.

Authors:  S R Edwards; R Braley; W L Chaffin
Journal:  FEMS Microbiol Lett       Date:  1999-08-15       Impact factor: 2.742

5.  Cross-species identification of novel Candida albicans immunogenic proteins by combination of two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.

Authors:  M Pardo; M Ward; A Pitarch; M Sánchez; C Nombela; W Blackstock; C Gil
Journal:  Electrophoresis       Date:  2000-07       Impact factor: 3.535

6.  Purification and some properties of Candida albicans exo-1,3-beta-glucanase.

Authors:  M Molina; R Cenamor; M Sanchez; C Nombela
Journal:  J Gen Microbiol       Date:  1989-02

7.  Tunicamycin and papulacandin B inhibit incorporation of specific mannoproteins into the wall of Candida albicans regenerating protoplasts.

Authors:  A Murgui; M V Elorza; R Sentandreu
Journal:  Biochim Biophys Acta       Date:  1986-12-10

8.  Cell wall of pathogenic yeasts and implications for antimycotic therapy.

Authors:  A Cassone
Journal:  Drugs Exp Clin Res       Date:  1986

9.  Nucleotide sequence of the exo-1,3-beta-glucanase-encoding gene, EXG1, of the yeast Saccharomyces cerevisiae.

Authors:  C R Vazquez de Aldana; J Correa; P San Segundo; A Bueno; A R Nebreda; E Mendez; F del Rey
Journal:  Gene       Date:  1991-01-15       Impact factor: 3.688

10.  Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans.

Authors:  R C Matthews; J P Burnie; S Tabaqchali
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

View more
  10 in total

1.  A screening assay based on host-pathogen interaction models identifies a set of novel antifungal benzimidazole derivatives.

Authors:  Anke Burger-Kentischer; Doris Finkelmeier; Petra Keller; Jörg Bauer; Holger Eickhoff; Gerald Kleymann; Walid Abu Rayyan; Anurag Singh; Klaus Schröppel; Karin Lemuth; Karl-Heinz Wiesmüller; Steffen Rupp
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

2.  Effect of Saccharomyces cerevisiae ret1-1 mutation on glycosylation and localization of the secretome.

Authors:  Ki-Hyun Kim; Eun-Kyung Kim; Su-Jin Kim; Yun-Hee Park; Hee-Moon Park
Journal:  Mol Cells       Date:  2010-11-25       Impact factor: 5.034

3.  Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.

Authors:  Jeniel Nett; Leslie Lincoln; Karen Marchillo; Randall Massey; Kathleen Holoyda; Brian Hoff; Michelle VanHandel; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-11-27       Impact factor: 5.191

4.  Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs.

Authors:  Zhu-Mei He; Jing Chen; Hong-Zhou Li; Di-Qing Luo; Wei Yang
Journal:  Folia Microbiol (Praha)       Date:  2010-05-19       Impact factor: 2.099

5.  Candida albicans virulence and drug-resistance requires the O-acyltransferase Gup1p.

Authors:  Célia Ferreira; Sónia Silva; Fábio Faria-Oliveira; Eva Pinho; Mariana Henriques; Cândida Lucas
Journal:  BMC Microbiol       Date:  2010-09-15       Impact factor: 3.605

6.  Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence.

Authors:  Hui-Ching Ko; Ting-Yin Hsiao; Chiung-Tong Chen; Yun-Liang Yang
Journal:  J Microbiol       Date:  2013-06-28       Impact factor: 3.422

7.  Proteomic analysis of Candida albicans cell walls reveals covalently bound carbohydrate-active enzymes and adhesins.

Authors:  Piet W J de Groot; Albert D de Boer; Jeff Cunningham; Henk L Dekker; Luitzen de Jong; Klaas J Hellingwerf; Chris de Koster; Frans M Klis
Journal:  Eukaryot Cell       Date:  2004-08

Review 8.  The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.

Authors:  Russell E Lewis; Pierluigi Viale; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

9.  Increasing Susceptibility of Drug-Resistant Candida albicans to Fluconazole and Terbinafine by 2(5H)-Furanone Derivative.

Authors:  Irshad S Sharafutdinov; Georgii D Ozhegov; Alina E Sabirova; Valentina V Novikova; Svetlana A Lisovskaya; Alsu M Khabibrakhmanova; Almira R Kurbangalieva; Mikhail I Bogachev; Airat R Kayumov
Journal:  Molecules       Date:  2020-02-02       Impact factor: 4.411

10.  Fluconazole Resistance Candida albicans in Females With Recurrent Vaginitis and Pir1 Overexpression.

Authors:  Zahra Nasrollahi; Mohammad Hossein Yadegari; Shahla Roudbar Mohammadi; Maryam Roudbary; Maryam Hosseini Poor; Fatemeh Nikoomanesh; Masumeh Rajabi Bazl
Journal:  Jundishapur J Microbiol       Date:  2015-09-23       Impact factor: 0.747

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.